Loading
Endometrial Adenocarcinoma / Laboratory Biomarker Analysis / BRCA1 Mutation Carrier · Phase 1 Trial
ClinicalTrials.gov · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1b/II dose-escalation trial registered at ClinicalTrials.gov (NCT02208375) evaluating olaparib combined with either vistusertib (AZD2014) or capivasertib (AZD5363) in patients with recurrent endometrial, ovarian, and related cancers. No efficacy or safety results are reported in this registry record; the trial is active but not recruiting as of this snapshot.
Phase 1, Interventional, Non Randomized, Parallel, Open label, Treatment purpose. BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Endometrial Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, High Grade Ovarian Serous Adenocarci…; Female; age from 18 Years. Intervention: Arm I (olaparib, vistusertib); Arm II (olaparib, vistusertib); Arm III (olaparib, capivasertib). n = 159. 1 site: United States.
This is a Phase 1b/II dose-escalation trial registered at ClinicalTrials.gov (NCT02208375) evaluating olaparib combined with either vistusertib (AZD2014) or capivasertib (AZD5363) in patients with recurrent endometrial, ovarian, and related cancers. No efficacy or safety results are reported in this registry record; the trial is active but not recruiting as of this snapshot.
This is a trial registration record; no clinical outcomes, efficacy data, safety data, or results are reported.
The source did not state who this applies to in practice.
Phase 1b/II dose-escalation trial with planned enrollment and no results yet reported in this registry record; early-phase design focused on safety and maximum tolerated dose.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT02208375). This is a study registration, not published results. Lead sponsor: M.D. Anderson Cancer Center. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 159 participants (ACTUAL). Conditions: BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Endometrial Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, High Grade Ovarian Serous Adenocarcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Uterine Corpus Cancer AJCC v7, Triple-Negative Breast Carcinoma. Interventions: DRUG: Capivasertib; OTHER: Laboratory Biomarker Analysis; DRUG: Olaparib; OTHER: Pharmacological Study; DRUG: Vistusertib. Primary outcome measures: Maximum tolerated dose , Up to 28 days. Brief summary: This phase Ib/II trial studies the side effects and best dose of olaparib and vistusertib (AZD2014) or olaparib and capivasertib (AZD5363) when given together in treating patients with endometrial, triple negative breast cancer, ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent). Olaparib, vistusertib, and capivasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.